Table 1.
Basal characteristics of the retained study population (n = 71).
| Data at enrolment | |||
|---|---|---|---|
| Age (years) | 65 ± 10 | ||
| Males (n, %) | 61 | 86% | |
| NYHA II (n, %) | 65 | 82% | |
| NYHA III (n, %) | 14 | 18% | |
| SBP (mmHg) | 115 ± 16 | ||
| DBP (mmHg) | 73 ± 9 | ||
| Heart rate (bpm) | 68 ± 11 | ||
| BMI (kg/m2) | 26.9 ± 4.3 | ||
| NT-proBNP (pg/ml) | 1,196 [648–2,891] | ||
| Hemoglobin (g/dl) | 14.3 ± 1.6 | ||
| Creatinine (mg/dl) | 1.20 ± 0.26 | ||
| GFR (ml/min/1,73 m2) | 66 ± 17 | ||
| Sodium (mmol/l) | 141 ± 3 | ||
| Potassium (mmol/l) | 4.32 ± 0.42 | ||
| Therapy | |||
| ACE-I (n, %) | 53 | 75% | |
| ARBs (n, %) | 16 | 23% | |
| Beta blockers (n, %) | 70 | 99% | |
| MRA (n, %) | 49 | 69% | |
| Diuretic (n, %) | 57 | 80% | |
| Ivabradine (n, %) | 9 | 13% | |
| Digoxin (n, %) | 6 | 8% | |
| Amiodarone (n, %) | 30 | 42% | |
NYHA, New York Heart Association; SBP, systolic blood pressure; DBP, diastolic blood pressure; BMI, body mass index; NT-proBNP, amino terminal pro-B-type natriuretic peptide; GFR, glomerular filtration rate assessed by Modification of Diet in Renal Disease (MDRD) equation; ACE-I, angiotensin-converting-enzyme inhibitors; ARBs, angiotensin receptor blockers; MRA, mineralocorticoid receptor antagonists.